Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case.

Abstract

Daily treatment of systemic mastocytosis with high-dose interferon-alfa often is not tolerated because of clinical or hematologic side effects. We report successful treatment of a patient with systemic mastocytosis, who was positive for the D816V mutation, with interferon alfa-2b at 10 million units three times per week. During 5 years of treatment, bone marrow infiltration by mast cells decreased from 50 to < or =5%, and there was a decrease (urinary N-methylhistamine excretion, 75%; serum tryptase concentration, 98%) or normalization (serum calcitonin value, urinary prostaglandin F2alpha excretion) of mast cell mediators. Side effects included mild depression (untreated) and biochemical hypothyroidism easily managed with supplemental levothyroxine.

• Authors: Joseph H Butterfield, Ayalew Tefferi, Gerald F Kozuh
• Journal: Leukemia research (Leuk Res) Vol. 29 Issue 2 Pg. 131-4 (Feb 2005) ISSN: 0145-2126 [Print] England
• PMID: 15607359 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interferon-alpha

Topics

• Adult
• Dose-Response Relationship, Drug
• Follow-Up Studies
• Humans
• Interferon-alpha (therapeutic use)
• Male
• Mastocytosis, Systemic (drug therapy)
• Treatment Outcome